A New Dawn in Ovarian Cancer: Relacorilant Rewrites the Odds!
- HOPE IGNITED: Relacorilant dramatically extends survival for women battling aggressive, platinum-resistant ovarian cancer, a disease with historically grim prognoses.
- LIFE-CHANGING DATA: The groundbreaking ROSELLA trial reveals a 30% cut in disease progression and, in an interim analysis, a 31% lower risk of death when Relacorilant is added to chemotherapy, without increasing side effects.
- A NEW STANDARD BECKONS: This innovative, well-tolerated therapy shows strong potential to transform care for a wide range of patients, offering precious more time and improved quality of life.
The fight against platinum-resistant ovarian cancer, a relentless disease that often leaves patients with dwindling options and a median survival of roughly 12 months on single-agent chemotherapy, has just witnessed a seismic shift. Corcept Therapeutics today unveiled stunning data from its pivotal Phase 3 ROSELLA trial in a late-breaking presentation at the ASCO 2025 Annual Meeting, with the findings simultaneously published in the prestigious journal, The Lancet. Their investigational drug, Relacorilant, when combined with nab-paclitaxel, is offering profound new hope.
Imagine a treatment that not only significantly slows the relentless march of cancer but also grants patients substantially more time. Relacorilant achieved just that, slashing the risk of disease progression by a remarkable 30%. Median progression-free survival was extended to 6.5 months compared to 5.5 months with chemotherapy alone. Even more profoundly, an interim analysis of overall survival showed Relacorilant reduced the risk of death by 31%, extending median survival to an incredible 16.0 months from 11.5 months.
This isn't just about statistics; it's about more sunrises, more cherished moments, more life. Relacorilant works by ingeniously modulating cortisol, a hormone whose activity can help tumors resist chemotherapy3, 5. By selectively blocking cortisol's effects at the glucocorticoid receptor, Relacorilant helps restore the cancer cells' vulnerability to treatment. Crucially, this powerful benefit comes without adding to the patient's safety burden and even led to a lower incidence of ascites. Unlike treatments that require specific biomarkers, Relacorilant's efficacy was seen broadly3, 6, positioning it, as Principal Investigator Dr. Alexander B. Olawaiye suggests, as a potential "new standard-of-care treatment." Corcept is now working to bring this potential lifeline to patients in the U.S. and Europe as swiftly as possible.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.